269 related articles for article (PubMed ID: 3318323)
21. Mutagenicity studies of muroctasin.
Shimada H; Hattori C; Sato T
Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
[TBL] [Abstract][Full Text] [Related]
22. Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues.
Saiki I; Saito S; Fujita C; Ishida H; Iida J; Murata J; Hasegawa A; Azuma I
Vaccine; 1988 Jun; 6(3):238-44. PubMed ID: 2844032
[TBL] [Abstract][Full Text] [Related]
23. Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer.
Yanagawa H; Haku T; Takeuchi E; Suzuki Y; Nokihara H; Sone S
Lung Cancer; 2000 Feb; 27(2):67-73. PubMed ID: 10688489
[TBL] [Abstract][Full Text] [Related]
24. General pharmacological properties of muroctasin.
Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
[TBL] [Abstract][Full Text] [Related]
25. A synthetic NOD2 agonist, muramyl dipeptide (MDP)-Lys (L18) and IFN-β synergistically induce dendritic cell maturation with augmented IL-12 production and suppress melanoma growth.
Fujimura T; Yamasaki K; Hidaka T; Ito Y; Aiba S
J Dermatol Sci; 2011 May; 62(2):107-15. PubMed ID: 21411292
[TBL] [Abstract][Full Text] [Related]
26. Subacute toxicity of muroctasin in mice and dogs.
Ono Y; Iwasaki T; Sekiguchi M; Onodera T
Arzneimittelforschung; 1988 Jul; 38(7A):1024-7. PubMed ID: 3190795
[TBL] [Abstract][Full Text] [Related]
27. Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine.
Matsumoto K; Otani T; Une T; Osada Y; Ogawa H; Azuma I
Infect Immun; 1983 Mar; 39(3):1029-40. PubMed ID: 6341226
[TBL] [Abstract][Full Text] [Related]
28. Muramyl dipeptide-Lys stimulates the function of human dendritic cells.
Todate A; Suda T; Kuwata H; Chida K; Nakamura H
J Leukoc Biol; 2001 Nov; 70(5):723-9. PubMed ID: 11698491
[TBL] [Abstract][Full Text] [Related]
29. Effect of muramyl dipeptide analog on Salmonella enteritidis infection in beige mice with Chediak-Higashi syndrome.
Onozuka K; Saito-Taki T; Nakano M
Microbiol Immunol; 1984; 28(11):1211-21. PubMed ID: 6097802
[TBL] [Abstract][Full Text] [Related]
30. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
[TBL] [Abstract][Full Text] [Related]
31. Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen.
Tamura M; Yoo YC; Yoshimatsu K; Yoshida R; Oka T; Ohkuma K; Arikawa J; Azuma I
Vaccine; 1995 Jan; 13(1):77-82. PubMed ID: 7762283
[TBL] [Abstract][Full Text] [Related]
32. Differences in interleukin 1 (IL-1), IL-6, tumor necrosis factor and IL-1 receptor antagonist production by human monocytes stimulated with muramyl dipeptide (MDP) and its stearoyl derivative, romurtide.
Suzuki K; Torii K; Hida S; Hayashi H; Hiyama Y; Oomoto Y; Takii T; Chiba T; Onozaki K
Immunopharmacology; 1994; 28(1):31-8. PubMed ID: 7928300
[TBL] [Abstract][Full Text] [Related]
33. Biotransformation of muroctasin in mice.
Matsubayashi K; Takegoshi T
Arzneimittelforschung; 1988 Jul; 38(7A):1015-8. PubMed ID: 3190793
[TBL] [Abstract][Full Text] [Related]
34. Local tolerance of muroctasin injection in rabbits.
Nakashima K; Jindo T; Nomura M
Arzneimittelforschung; 1988 Jul; 38(7A):1038-9. PubMed ID: 3190798
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of mitogen-induced polyclonal activation by by a synthetic adjuvant, muramyl dipeptide (MDP).
Löwy I; Leclerc C; Bourgeois E; Chedid L
J Immunol; 1980 Jan; 124(1):320-5. PubMed ID: 6985643
[TBL] [Abstract][Full Text] [Related]
36. Stimulation of the in vivo dinitrophenyl antibody response to the DNP conjugate of L-glutamic acid60-L-alanine30-L-Tyrosine10 (GAT) polymer by a synthetic adjuvant, muramyl dipeptide (MDP): target cells for adjuvant activity and isotypic pattern of MDP-stimulated response.
Lowy I; Theze J; Chedid L
J Immunol; 1980 Jan; 124(1):100-4. PubMed ID: 6965289
[TBL] [Abstract][Full Text] [Related]
37. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
Ishihara C; Yamamoto K; Hamada N; Azuma I
Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
[TBL] [Abstract][Full Text] [Related]
38. Chronic toxicity of muroctasin in mice.
Ono Y; Sekiguchi M; Aihara K; Onodera T
Arzneimittelforschung; 1988 Jul; 38(7A):1028-30. PubMed ID: 3190796
[TBL] [Abstract][Full Text] [Related]
39. Muroctasin. A new muramyl dipeptide derivative, MDP-Lys(L18).
Arzneimittelforschung; 1988 Jul; 38(7A):951-1074. PubMed ID: 3190801
[No Abstract] [Full Text] [Related]
40. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.
Tsubura E; Nomura T; Niitani H; Osamura S; Okawa T; Tanaka M; Ota K; Nishikawa H; Masaoka T; Fukuoka M
Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
